ArticleNorth American Spine Society journal2025
Can oral caffeine decrease postoperative opioid consumption following posterior spinal fusion in adolescent idiopathic scoliosis? A randomized placebo-controlled trial.
Article in North American Spine Society journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Current studies have examined the efficacy of opioid-sparing analgesics primarily in adult surgical populations, while fewer guide pediatric postoperative pain treatment. Caffeine exerts most of its biological effects by binding to adenosine receptors, which are important for modifying pain and inflammation. Caffeine's ability to modulate pain following posterior spinal fusion (PSF) for adolescent idiopathic scoliosis (AIS) has not been previously assessed. Methods: The hospital investigational drug study (IDS) pharmacy provided either a treatment dose or placebo dose of caffeine to be given to the patient and was also in charge of randomization for the study. Results: There were 24 patients in the caffeine group (mean 14.3±1.5 years, 91.7% female) and 27 in the control group (mean 14.8±1.4 years, 88.9% female). Postoperative opioid usage was lower in the caffeine cohort for POD 1 (18.6 MME vs. 21.6 MME; p=.19), but this difference was not statistically significant. Opioid usage decreased in the caffeine study group for POD 1 (caffeine: 0.35 MME/kg vs. 0.4 MME/kg; p=.19) and mean daily total opioid usage over the hospital stay (caffeine: 0.32 MME/kg vs. 0.37 MME/kg; p=1), but these differences were not statistically significant. The caffeine study group demonstrated a mean reduction in total opioid consumption over the hospital stay of 5 MME. Conclusions: Oral caffeine use resulted in an average reduction of 5 MME opioid consumption, equivalent to 5 mg of hydrocodone. While this trial was underpowered to definitively assess the outcome, oral caffeine shows potential as an adjunct medication for opioid stewardship in AIS patients. This trial's reported mean total oral opioid consumption range of 0.83 to 0.92 MME/kg is lower than the amounts typically observed in clinical trials. This finding could indicate a successful strategy in reducing opioid use, which aligns with current medical efforts for opioid stewardship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.